Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Cannabis Program Operations topic
No spam. Unsubscribe anytime.
Board hears program update, raises concerns about dispensary pharmacist role and medical product availability
Summary
The Board received program statistics from Lila McKinley and discussed pharmacist consultations, product shortages for medical patients, concentration caps and the need for clinician and pharmacist education; members asked staff to arrange informational sessions with pharmacists, dispensary operators and growers
Lila McKinley, director of the agency’s cannabis program, told the Board of Physicians on May 16 that the program has grown and provided current enrollment and supply figures.
McKinley said the program has about 1,892 registered practitioners and 34,006 registered patients, and reported there are 35 hybrid dispensaries (facilities serving both medical and adult-use customers), two cultivators and six microcultivators now supplying the market.
Board members raised operational concerns during an extended discussion. Several physicians said medical patients sometimes cannot obtain lower-dose or combination products (for example THC combined with CBD or CBG) and that dispensaries appear more focused on higher‑THC adult‑use products. Dr. Pearlson and Dr. Barry urged clearer access to lower-dose medical formulations and better mechanisms for initial patient consultation.
McKinley said the department requires pharmacists to dispense all medical product and that facilities must have a pharmacist on site at least 40 hours a week under current law; she also said dispensaries typically provide an initial pharmacist consultation to help with registration and dosing, although the consultation requirement is implemented through operating procedures tied to the RFA rather than an explicit regulatory mandate. “We require that all of the medical product be dispensed by a pharmacist,” McKinley said, and pharmacists check the PDMP before dispensing.
Board members asked whether the pharmacist role is mandatory for the initial consult and how staffing varies by facility; McKinley answered that there is a required consultation space and a staffing ratio that in practice mirrors pharmacy norms but that consultation frequency can vary by facility. Members also described variability across dispensaries in how consultations are performed and questioned whether pharmacists consistently collect medication lists, weights or other clinical details when advising patients. Dr. Zabbski called for more program‑level data on quality measures and patient satisfaction; several members urged staff to invite pharmacists, dispensary operators and growers to an informational session so the board could better understand day‑to‑day operations.
The board agreed to request staff coordination of an informational session after the legislative session, with possible site visits to production facilities. No rule changes or formal regulatory actions were taken at the meeting.
